3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Brain Neoplasms
4
Glioma
3
Thyroid Cancer, Papillary
2
Sarcoma
2
Salivary Gland Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Central Nervous System Neoplasms
2
Wilms Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Large-Cell, Anaplastic
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
7
gallium Ga 68 dotatate
6
lutetium Lu 177 dotatate
4
Fluorodeoxyglucose F18
3
3-Iodobenzylguanidine
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
fluorodopa F 18
2
Specimen Handling
2
FAPI-46
2
Everolimus
2
Erlotinib Hydrochloride
2
vandetanib
1
romidepsin
1
pertuzumab
1
pentetreotide
1
olaparib
1
fludarabine phosphate
1
entrectinib
1
dactolisib
1
cabozantinib
1
atezolizumab
1
arginyllysine
1
amino-acid, glucose, and electrolyte solution
1
alectinib
1
Whole Body Imaging
1
Tretinoin
1
Respiratory Therapy
1
Quality of Life
1
Positron-Emission Tomography
1
Patient Reported Outcome Measures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
entrectinib
×
CNS
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA